Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Group 1 - Vor Biopharma Inc. has priced an underwritten public offering of 10 million shares at $10.00 per share, expecting gross proceeds of $100 million [1] - The company has granted underwriters a 30-day option to purchase up to an additional 1.5 million shares [1] Group 2 - Vor Bio's collaborator, RemeGen Co., Ltd, reported positive results for telitacicept in treating autoimmune disorders, achieving statistically significant benefits across all secondary endpoints [4] - In a Phase 3 clinical study in China, telitacicept achieved the primary endpoint of reducing proteinuria, with a significant reduction in 24-hour urine protein-to-creatinine ratio compared to placebo (-58.9% vs. -8.8%) [8] - The study enrolled 318 adult patients and demonstrated that telitacicept stabilized kidney function, with a decline in the placebo group compared to a stabilization in the telitacicept group [5][8] Group 3 - Telitacicept showed a favorable safety profile, with treatment-emergent adverse events occurring more frequently but mostly being mild or moderate; serious adverse events were less common with telitacicept than with placebo [7] - The drug demonstrated significant efficacy, with 61% of patients on telitacicept achieving a 24h-UPCR <0.8 g/g compared to 19.5% on placebo [6]